Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Stifel Reiterates Buy Rating on Contineum Therapeutics (CTNM)
August 15, 2024 7:46 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $29.00 price target on Contineum Therapeutics (NASDAQ: CTNM).
The analyst comments "We remain Buy rated on CTNM following their 2Q24 earnings release. Our thesis on CTNM primarily centers around their LPA1 receptor antagonist... More
Contineum Therapeutics (CTNM) PT Raised to $32 at RBC Capital
August 14, 2024 6:24 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Contineum Therapeutics (NASDAQ: CTNM) to $32.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "Both key assets '791 and '307 remain on track, with near-term data PET imaging data for '791 having potential... More
